Can Alkermes' Vivitrol Live Up To Commercial Potential In Opioid Dependence?
This article was originally published in The Pink Sheet Daily
Executive Summary
Company does not plan to compete against market-leading Suboxone, and will initially target the newly addicted, such as young adults, and certain professionals who can't take available treatments.
You may also be interested in...
Titan Hopes To Tap Into Niche Drug Addiction Market With Six-Month Implant
Titan says compliance and abuse-resistance will hook payers on new long-acting formulations vs. low-cost generics.
Titan Hopes To Tap Into Niche Drug Addiction Market With Six-Month Implant
Titan says compliance and abuse-resistance will hook payers on new long-acting formulations vs. low-cost generics.
Alkermes Needs To Eject DVD Of Vivitrol Patient Testimonials, FDA Says
DDMAC also objects to a 24-page brochure for the alcoholism treatment that doesn't include any risk information until page 20.